Counterpoint Mutual Funds LLC Buys 3,065 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Counterpoint Mutual Funds LLC lifted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 20.1% in the fourth quarter, HoldingsChannel reports. The fund owned 18,341 shares of the company’s stock after buying an additional 3,065 shares during the period. Counterpoint Mutual Funds LLC’s holdings in Hims & Hers Health were worth $443,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. SlateStone Wealth LLC lifted its holdings in shares of Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after acquiring an additional 413 shares during the last quarter. Blume Capital Management Inc. lifted its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares during the last quarter. Harbour Investments Inc. lifted its holdings in shares of Hims & Hers Health by 18.8% in the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after acquiring an additional 833 shares during the last quarter. Finally, Stonekeep Investments LLC lifted its holdings in shares of Hims & Hers Health by 5.5% in the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after acquiring an additional 882 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Insider Transactions at Hims & Hers Health

In other news, insider Michael Chi sold 17,303 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $48.14, for a total value of $832,966.42. Following the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at $9,319,952.14. This represents a 8.20 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 268,932 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now directly owns 169,803 shares in the company, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 890,592 shares of company stock valued at $31,677,291 in the last three months. 17.71% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC boosted their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Bank of America reiterated an “underperform” rating and set a $21.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Leerink Partners upped their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Citigroup reiterated a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Finally, Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $42.00 to $60.00 in a report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $37.23.

Hims & Hers Health Trading Up 4.6 %

Shares of Hims & Hers Health stock opened at $34.68 on Tuesday. The company’s fifty day simple moving average is $38.64 and its two-hundred day simple moving average is $28.37. The company has a market cap of $7.70 billion, a P/E ratio of 78.82 and a beta of 1.37. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.